Shukra Pharmaceuticals files SEBI Reg. 32(1) compliance disclosure confirming no deviation in utilization of ₹3.95 crore preferential issue proceeds.
Company raised ₹3.95 crore as 25% consideration for 46.43 lakh convertible warrants issued at ₹1 each in November 2025 EGM.
Audit Committee reviewed and confirmed no deviation from objects stated in EGM notice for working capital and general corporate purposes.
Total fundraising under the preferential issue program amounts to ₹15.79 crore with full compliance to SEBI ICDR Regulations.